Obesity is often thought of as calories in versus calories out. But as the review by Steenackers and colleagues (2024) makes clear, the gastrointestinal (GI) tract itself is far from a passive bystander. From motility patterns to enzyme and bile acid secretion, the gut’s physiology may influence not only appetite and metabolism but also the risk of nutritional deficiencies and responses to treatment. 

A Complex and Variable Gut Environment 

Obesity is now widely recognized as a chronic, relapsing disease rather than a simple risk factor. While the gut’s role in appetite regulation via hormones and the microbiota has been widely studied, the review highlights that our understanding of basic GI functions — acidity, motility, transit time, and secretions — remains limited. Yet, these functions are central to how nutrients and medications are processed.

Interestingly, studies reveal substantial variability among people with obesity. For instance, data on gastric emptying are mixed: some studies show accelerated emptying, others show delays, and some find no difference compared with normal-weight individuals. These discrepancies may reflect differences in meal type, caloric load, and comorbidities like type 2 diabetes, which themselves alter motility and gastric function. 

What Happens in the Intestine? 

The small intestine, the main site for nutrient absorption, also shows altered transit times in obesity. Some studies suggest faster transit — potentially reducing absorption opportunities — while others report prolonged transit. This lack of consensus highlights the need for more standardized research. The colon, on the other hand, appears less affected, though obesity is linked to higher rates of impaired bowel function. 

Secretions and pH: Signals Beyond Digestion 

The review draws attention to the biochemical environment of the GI tract. Gastric acid secretion may be altered in obesity, but results are inconsistent, with studies showing both lower and unchanged gastric pH. In the small intestine, some findings point toward lower pH levels in people with obesity, which could influence both nutrient breakdown and microbiota composition. 

Enzyme secretion also shows notable shifts: 

• Amylase – an enzyme for carbohydrate digestion: Several studies report lower serum amylase levels with increasing adiposity, though the implications for starch digestion remain unclear.
• Trypsin – an enzyme for protein breakdown: Evidence is limited, but one study found higher basal trypsin secretion in obesity, with smaller responses to stimuli like cholecystokinin (CCK; a gut hormone released after nutrient sensing in the small intestine. It plays a central role in coordinating digestion and appetite regulation). The clinical relevance is still uncertain.
• Lipase – an enzyme for fat digestion: Basal lipase secretion seems similar between weight groups, but stimulated secretion (e.g., after a meal or CCK) may be higher in obesity. Given that lipase inhibition (via orlistat) is an established obesity therapy, these differences could be clinically meaningful. 

Bile Acids: A Key Player in Nutrient Absorption 

Perhaps the clearest evidence comes from studies on bile acids. Most reports show higher fasting bile acid levels but a blunted rise after meals in people with obesity. Since bile acids are essential for fat digestion and absorption — and also act as metabolic messengers interacting with the gut microbiota — this altered pattern could impact both energy intake and nutrient bioavailability. Importantly, bile acid dynamics may influence lipid absorption and postprandial triglyceride responses, with possible implications for cardiovascular risk. 

Key Takeaway 

We know that weight loss interventions such as bariatric surgery and medication increases the risk for micronutrient deficiencies. Moreover, many patients with obesity already experience nutrient deficiencies even before weight loss interventions. Altered bile acid and enzyme activity may contribute to suboptimal absorption of micronutrients such as iron, zinc, copper, vitamin D, and calcium. This underlines the importance of personalized nutritional monitoring and tailored supplementation strategies not only with weight loss interventions such bariatric surgery or medication, but also for people with obesity in general. 

The gut is not just a passive conduit in obesity — it is an active player in weight regulation, nutrient absorption, and metabolic health. For clinicians, this means paying close attention to GI function when managing patients with obesity. While research findings remain inconsistent in some areas, there is growing evidence that variations in motility, acidity, enzyme secretion, and bile acid dynamics can influence nutrient handling and treatment response. As our understanding deepens, targeting these physiological processes — and tailoring supplementation to individual needs — could become a valuable part of obesity management. 

Would you like to learn more about this research study?

Simply contact us using the button below: